Leggett & Platt Announces 1Q 2025 Results Carthage, MO, April 15, 2025 (GLOBE NEWSWIRE) -- Leggett & Platt (NYSE:LEG), a diversified manufacturer of engineered products serving several major markets, will release first quarter earnings results on Monday, April 28, 2025 after the market closes, and hold its quarterly conference call to discuss first quarter results, annual guidance, market conditions, company initiatives and related matters on Tuesday, April 29, 2025, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). This call will be webcast and can be accessed from the Investor Relati...
Norwegian Cruise Line Holdings Announces Development Plans for Private Island Destination, Great Stirrup Cay Infrastructure Enhancements to Elevate Guest Experience and Support Multi-Ship Pier Beginning in Fourth Quarter 2025 MIAMI, April 13, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) today announced plans to build out new amenities and enhancements at Great Stirrup Cay, its private island destination in the Bahamas. The upgrades are scheduled to debut in the fourth quarter of 2025 alongside the completion of a new multi-ship pier. The enhancements includ...
Norwegian Cruise Line Holdings to Hold Conference Call on First Quarter 2025 Financial Results MIAMI, April 10, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings” or the “Company”) announced today it will report first quarter 2025 financial results on Wednesday, April 30, 2025 at 6:30 a.m. Eastern Time with a conference call and webcast to discuss results at 8:00 a.m. Eastern Time. The conference call will be webcast via the Company’s Investor Relations website, . A replay of the webcast will be ...
Norwegian Cruise Line Holdings Announces Charter Agreements for Four Vessels Charters contribute to Company’s fleet optimization efforts under its Charting the Course strategy MIAMI, April 07, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) today announced the execution of long-term charter agreements, each inclusive of purchase options, for four vessels across its three brands. The agreements are for: Two Norwegian Cruise Line vessels, Norwegian Sky and Norwegian Sun, to be chartered to Cordelia Cruises, a premium cruise operator based in India. The charters...
Treace Announces Upcoming Board Chair Transition PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace, as the Chairman of the Board to be effective immediately following the 2025 annual meeting of stockholders. Mr. John. T. Treace w...
Norwegian Cruise Line Holdings Ltd. and NCL Corporation Ltd. Announce Additional Exchangeable Notes Refinancing Transaction MIAMI, April 03, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (the “Company”) and NCL Corporation Ltd., a subsidiary of the Company (“NCLC”), announce that, in addition to the previously disclosed exchange entered into on April 1, 2025 (the “First Exchange”), NCLC has entered into individually negotiated note exchange agreements with certain existing holders (the “Holders”) of NCLC’s 5.375% Exchangeable Senior Notes due 2025 (the “2025 No...
Norwegian Cruise Line Holdings Ltd. and NCL Corporation Ltd. Announce Exchangeable Notes Refinancing Transaction MIAMI, April 02, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (the “Company”) and NCL Corporation Ltd., a subsidiary of the Company (“NCLC”), announce that NCLC has entered into individually negotiated note exchange agreements with certain existing holders (the “Holders”) of NCLC’s 5.375% Exchangeable Senior Notes due 2025 (the “2025 Notes”), pursuant to which NCLC and the Holders have agreed to exchange (the “Exchange”) $285,425,000 in aggregate pr...
Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, as well as the first presentation of ...
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Commenced market launch and first commercial sales of Symvess - - Budget Impact Model for Symvess published in Journal of Medical Economics - - IND filing planned in 2025 to support first-in-human clinical study of small-diameter ATEV™ for coronary artery bypass grafting - - Conference call today at 8:30am ET - DURHAM, N.C., ...
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025 DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31, 2024, on Friday, March 28, 2025. Management will host a webcast and conference call at 8:30 a.m. ET. Title:Humacyte Fourth Quarter and Full Year 2024 Financial Results and Corporate...
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expens...
Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference Expands market-leading position with new best-in-class bunion technologies PONTE VEDRA, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced new technology innovations featured at the 2025 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Confer...
Humacyte, Inc. Announces Proposed Public Offering of Common Stock DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering of its common stock. In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares a...
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics – Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – Publication of the Budget Impact Model in peer-reviewed journal supports Symvess as a treatment that provides economic value to hospitals and payers – DURHAM, N.C., March 10, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing u...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.